Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR-T, Allo-HSCT, and Kidney Transplant for SIOD
NCT06769191Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD7 CAR-T cells injection in Schimke immuno-osseous dysplasia (SIOD), sponsored by Zhejiang University. Primary endpoints: Incidence of treatment-emergent adverse events at 2 years and Transplant related mortality rate at 100 days. Started Jan 2025; status: recruiting.
02
Drugs
CD7 CAR-T cells injection
03
Conditions
Schimke immuno-osseous dysplasia (SIOD)
Beyond the preview
Go deeper on NCT06769191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06769191.